|Bid||12.76 x 800|
|Ask||13.00 x 800|
|Day's Range||12.72 - 13.63|
|52 Week Range||3.02 - 22.49|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.32|
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today that it has signed a contract to provide its digital therapeutics solution to eligible employees of a U.S.-based Fortune 500 technology company.
DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (DTS), which showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario's digital therapeutics platform (Dario DTx).
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / DarioHealth Corp.